Regulation of glutathione in cardiac myocytes

Shumin Li, Xun Li, George J Rozanski

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Reduced glutathione (GSH) is an essential, multifunctional tripepetide that controls redox-sensitive cellular processes, but its regulation in the heart is poorly understood. The present study used a pharmocological model of GSH depletion to examine cellular mechanisms controlling cardiac GSH. Inhibition of GSH metabolism was elicited in normal rats by daily injections of buthionine sulfoximine (BSO), a blocker of γ-glutamylcysteine synthetase, plus 1, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), an inhibitor of glutathione reductase. After 3 d of BSO/BCNU treatment, intracellular [GSH] was measured in isolated-ventricular myocytes by fluorescence microscopy using the probe monochlorobimane. Basal [GSH] in left-ventricular myocytes from BSO/ BCNU-treated rats (2.0 ± 0.05 amol/μm3, n = 146) was 50% less than control (4.0 ± 0.13 amol/μm3, n = 116; P < 0.05). Incubation of myocytes from BSO/BCNU rats with 0.1 μM insulin normalized [GSH] after a delay of 3-4 h (3.6 ± 0.29 amol/μm 3, n = 66). This effect of insulin was blocked by pre-treating myocytes with cycloheximide. A protein tyrosine phosphatase inhibitor, bis-peroxovanadium-1, 10-phenanthroline (bpV(phen), 1 μM), elicited a similar effect as insulin, while neither agent altered [GSH] in myocytes from control rats. Moreover, the effect of insulin and bpV(phen) to up-regulate GSH was blocked by inhibitors of PI 3-kinase (wortmannin, LY294002), MEK (PD98059) and p38 MAP kinases (SB203580). These data suggest that the insulin-signaling cascade regulates [GSH] in ventricular myocytes by a coordinated activation of PI 3-kinase and MAP kinase pathways. These signaling mechanisms may play essential roles in controlling intracellular redox state and normal function of cardiac myocytes.

Original languageEnglish (US)
Pages (from-to)1145-1152
Number of pages8
JournalJournal of Molecular and Cellular Cardiology
Volume35
Issue number9
DOIs
StatePublished - Sep 1 2003

Fingerprint

Carmustine
Cardiac Myocytes
Muscle Cells
Buthionine Sulfoximine
Glutathione
Insulin
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Oxidation-Reduction
Glutamate-Cysteine Ligase
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Protein Tyrosine Phosphatases
Glutathione Reductase
p38 Mitogen-Activated Protein Kinases
Cycloheximide
Fluorescence Microscopy
Up-Regulation
Injections

Keywords

  • Glutathione
  • Insulin
  • MAP kinase
  • Myocyte
  • PI 3-kinase
  • Redox

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Regulation of glutathione in cardiac myocytes. / Li, Shumin; Li, Xun; Rozanski, George J.

In: Journal of Molecular and Cellular Cardiology, Vol. 35, No. 9, 01.09.2003, p. 1145-1152.

Research output: Contribution to journalArticle

Li, Shumin ; Li, Xun ; Rozanski, George J. / Regulation of glutathione in cardiac myocytes. In: Journal of Molecular and Cellular Cardiology. 2003 ; Vol. 35, No. 9. pp. 1145-1152.
@article{0790bbdc925649edb4a5f42d741b68c3,
title = "Regulation of glutathione in cardiac myocytes",
abstract = "Reduced glutathione (GSH) is an essential, multifunctional tripepetide that controls redox-sensitive cellular processes, but its regulation in the heart is poorly understood. The present study used a pharmocological model of GSH depletion to examine cellular mechanisms controlling cardiac GSH. Inhibition of GSH metabolism was elicited in normal rats by daily injections of buthionine sulfoximine (BSO), a blocker of γ-glutamylcysteine synthetase, plus 1, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), an inhibitor of glutathione reductase. After 3 d of BSO/BCNU treatment, intracellular [GSH] was measured in isolated-ventricular myocytes by fluorescence microscopy using the probe monochlorobimane. Basal [GSH] in left-ventricular myocytes from BSO/ BCNU-treated rats (2.0 ± 0.05 amol/μm3, n = 146) was 50{\%} less than control (4.0 ± 0.13 amol/μm3, n = 116; P < 0.05). Incubation of myocytes from BSO/BCNU rats with 0.1 μM insulin normalized [GSH] after a delay of 3-4 h (3.6 ± 0.29 amol/μm 3, n = 66). This effect of insulin was blocked by pre-treating myocytes with cycloheximide. A protein tyrosine phosphatase inhibitor, bis-peroxovanadium-1, 10-phenanthroline (bpV(phen), 1 μM), elicited a similar effect as insulin, while neither agent altered [GSH] in myocytes from control rats. Moreover, the effect of insulin and bpV(phen) to up-regulate GSH was blocked by inhibitors of PI 3-kinase (wortmannin, LY294002), MEK (PD98059) and p38 MAP kinases (SB203580). These data suggest that the insulin-signaling cascade regulates [GSH] in ventricular myocytes by a coordinated activation of PI 3-kinase and MAP kinase pathways. These signaling mechanisms may play essential roles in controlling intracellular redox state and normal function of cardiac myocytes.",
keywords = "Glutathione, Insulin, MAP kinase, Myocyte, PI 3-kinase, Redox",
author = "Shumin Li and Xun Li and Rozanski, {George J}",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0022-2828(03)00230-X",
language = "English (US)",
volume = "35",
pages = "1145--1152",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "9",

}

TY - JOUR

T1 - Regulation of glutathione in cardiac myocytes

AU - Li, Shumin

AU - Li, Xun

AU - Rozanski, George J

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Reduced glutathione (GSH) is an essential, multifunctional tripepetide that controls redox-sensitive cellular processes, but its regulation in the heart is poorly understood. The present study used a pharmocological model of GSH depletion to examine cellular mechanisms controlling cardiac GSH. Inhibition of GSH metabolism was elicited in normal rats by daily injections of buthionine sulfoximine (BSO), a blocker of γ-glutamylcysteine synthetase, plus 1, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), an inhibitor of glutathione reductase. After 3 d of BSO/BCNU treatment, intracellular [GSH] was measured in isolated-ventricular myocytes by fluorescence microscopy using the probe monochlorobimane. Basal [GSH] in left-ventricular myocytes from BSO/ BCNU-treated rats (2.0 ± 0.05 amol/μm3, n = 146) was 50% less than control (4.0 ± 0.13 amol/μm3, n = 116; P < 0.05). Incubation of myocytes from BSO/BCNU rats with 0.1 μM insulin normalized [GSH] after a delay of 3-4 h (3.6 ± 0.29 amol/μm 3, n = 66). This effect of insulin was blocked by pre-treating myocytes with cycloheximide. A protein tyrosine phosphatase inhibitor, bis-peroxovanadium-1, 10-phenanthroline (bpV(phen), 1 μM), elicited a similar effect as insulin, while neither agent altered [GSH] in myocytes from control rats. Moreover, the effect of insulin and bpV(phen) to up-regulate GSH was blocked by inhibitors of PI 3-kinase (wortmannin, LY294002), MEK (PD98059) and p38 MAP kinases (SB203580). These data suggest that the insulin-signaling cascade regulates [GSH] in ventricular myocytes by a coordinated activation of PI 3-kinase and MAP kinase pathways. These signaling mechanisms may play essential roles in controlling intracellular redox state and normal function of cardiac myocytes.

AB - Reduced glutathione (GSH) is an essential, multifunctional tripepetide that controls redox-sensitive cellular processes, but its regulation in the heart is poorly understood. The present study used a pharmocological model of GSH depletion to examine cellular mechanisms controlling cardiac GSH. Inhibition of GSH metabolism was elicited in normal rats by daily injections of buthionine sulfoximine (BSO), a blocker of γ-glutamylcysteine synthetase, plus 1, 3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), an inhibitor of glutathione reductase. After 3 d of BSO/BCNU treatment, intracellular [GSH] was measured in isolated-ventricular myocytes by fluorescence microscopy using the probe monochlorobimane. Basal [GSH] in left-ventricular myocytes from BSO/ BCNU-treated rats (2.0 ± 0.05 amol/μm3, n = 146) was 50% less than control (4.0 ± 0.13 amol/μm3, n = 116; P < 0.05). Incubation of myocytes from BSO/BCNU rats with 0.1 μM insulin normalized [GSH] after a delay of 3-4 h (3.6 ± 0.29 amol/μm 3, n = 66). This effect of insulin was blocked by pre-treating myocytes with cycloheximide. A protein tyrosine phosphatase inhibitor, bis-peroxovanadium-1, 10-phenanthroline (bpV(phen), 1 μM), elicited a similar effect as insulin, while neither agent altered [GSH] in myocytes from control rats. Moreover, the effect of insulin and bpV(phen) to up-regulate GSH was blocked by inhibitors of PI 3-kinase (wortmannin, LY294002), MEK (PD98059) and p38 MAP kinases (SB203580). These data suggest that the insulin-signaling cascade regulates [GSH] in ventricular myocytes by a coordinated activation of PI 3-kinase and MAP kinase pathways. These signaling mechanisms may play essential roles in controlling intracellular redox state and normal function of cardiac myocytes.

KW - Glutathione

KW - Insulin

KW - MAP kinase

KW - Myocyte

KW - PI 3-kinase

KW - Redox

UR - http://www.scopus.com/inward/record.url?scp=0042831502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042831502&partnerID=8YFLogxK

U2 - 10.1016/S0022-2828(03)00230-X

DO - 10.1016/S0022-2828(03)00230-X

M3 - Article

VL - 35

SP - 1145

EP - 1152

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 9

ER -